Kenvue Inc. (NYSE:KVUE) Receives $23.08 Average Price Target from Analysts

Kenvue Inc. (NYSE:KVUE) has earned a consensus rating of “Hold” from the twelve ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $23.08.

KVUE has been the subject of a number of research analyst reports. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $21.00 to $26.00 in a report on Monday, January 6th. UBS Group cut their target price on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a research note on Thursday, January 16th. Barclays decreased their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th. Royal Bank of Canada raised shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. Finally, Bank of America lifted their target price on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd.

Kenvue Price Performance

NYSE KVUE opened at $20.79 on Friday. Kenvue has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a fifty day simple moving average of $22.14 and a 200 day simple moving average of $21.78. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a market cap of $39.85 billion, a P/E ratio of 37.79, a P/E/G ratio of 1.99 and a beta of 1.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same period in the prior year, the company earned $0.31 earnings per share. The business’s quarterly revenue was down .4% compared to the same quarter last year. On average, sell-side analysts predict that Kenvue will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.95%. Kenvue’s payout ratio is presently 149.09%.

Institutional Investors Weigh In On Kenvue

Several large investors have recently made changes to their positions in KVUE. Flavin Financial Services Inc. acquired a new position in Kenvue in the fourth quarter valued at about $964,000. Columbus Macro LLC boosted its holdings in shares of Kenvue by 203.1% in the 4th quarter. Columbus Macro LLC now owns 223,588 shares of the company’s stock worth $4,774,000 after acquiring an additional 149,819 shares in the last quarter. Childress Capital Advisors LLC grew its position in Kenvue by 11.4% during the 4th quarter. Childress Capital Advisors LLC now owns 16,090 shares of the company’s stock worth $344,000 after acquiring an additional 1,642 shares during the last quarter. Renaissance Capital LLC raised its position in Kenvue by 9.3% in the 4th quarter. Renaissance Capital LLC now owns 723,592 shares of the company’s stock valued at $15,449,000 after purchasing an additional 61,330 shares during the last quarter. Finally, One Wealth Advisors LLC raised its position in Kenvue by 31.4% in the 4th quarter. One Wealth Advisors LLC now owns 12,131 shares of the company’s stock valued at $259,000 after purchasing an additional 2,897 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.